Drugs / LYL845
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05573035 | Dec 2022 → Jan 2025 | colorectal cancer, melanoma, non-small cell lung carcinoma | Lyell Immunopharma, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYL845 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05573035 ↗ |
| Modality | Cell therapy | “epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy” NCT05573035 ↗ |